Oxycon - Pharmacology:

Oxycon acts as a weak agonist at mu, kappa, and delta opioid receptors within the central nervous system (CNS). Oxycon primarily affects mu-type opioid receptors, which are coupled with G-protein receptors and function as modulators, both positive and negative, of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine, and noradrenaline is inhibited. Opioids such as oxycodone also inhibit the release of vasopressin, somatostatin, insulin, and glucagon. Opioids close N-type voltage-operated calcium channels (kappa-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (mu and delta receptor agonist). This results in hyperpolarization and reduced neuronal excitability.

Oxycon for patients

WARNINGS

Drug Dependence: Oxycon can produce drug dependence of the morphine type, and therefore, has the
potential for being abused. Psychic dependence, physical dependence and tolerance may develop upon repeated
administration of this drug, and it should be prescribed and administered with the same degree of caution appropriate
to the use of other oral narcotic-containing medications. Like other narcotic-containing medications, this drug is
subject to the Federal Controlled Substances Act.

Usage in Ambulatory Patients: Oxycon may impair the mental and/or physical abilities required for
the performance of potentially hazardous tasks such as driving a car or operating machinery. The patient using this
drug should be cautioned accordingly.

Interaction with Other Central Nervous System Depressants: Patients receiving other narcotic
analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics or other CNS depressants
(including alcohol) concomitantly with oxycodone hydrochloride may exhibit an additive CNS depression. When such
combined therapy is contemplated, the dose of one or both agents should be reduced.

Usage in Pregnancy: Safe use in pregnancy has not been established relative to possible adverse
effects on fetal development. Therefore, this drug should not be used in pregnant women unless, in the judgment of
the physician, the potential benefits outweigh the possible hazards.

Usage in Children: This drug should not be administered to children.

PRECAUTIONS

Head Injury and Increased Intracranial Pressure: The respiratory depressant effects of narcotics and
their capacity to elevate cerebrospinal fluid pressure may be markedly exaggerated in the presence of head injury,
other intracranial lesions or a pre-existing increase in intracranial pressure. Furthermore, narcotics produce
adverse reactions which may obscure the clinical course of patients with head injuries.

Acute Abdominal Conditions: The administration of this drug or other narcotics may obscure the
diagnosis or clinical course in patients with acute abdominal conditions.

Special Risk Patients: This drug should be given with caution to certain patients such as the
elderly, or debilitated, and those with severe impairment of hepatic or renal function, hypothyroidism, Addisons
disease and prostatic hypertrophy or urethral stricture.

Oxycon Interactions

The CNS depressant effects of oxycodone hydrochloride may be additive with that of other CNS depressants..